← All trials
NCT02658409
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2015
- Primary completion
- Nov 1, 2015
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 1630
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Green Cross CorporationLead sponsor
- Korea UniversityStudy director
- Columbia UniversityStudy director
- Chonnam National UniversityStudy director
- Hallym UniversityStudy director
- Inha UniversityStudy director
- Kyungpook UniversityStudy director
- Soonchunhyang UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.